Published in:
01-12-2017 | Original Article
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer
Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2017
Login to get accessAbstract
Purpose
The potential inhibition of CYP3A4 by lapatinib was studied using midazolam as a probe substrate in patients with cancer.
Methods
This was a partially randomized, 4-period, 4-sequence, 4-treatment, cross-over study in 24 patients with advanced cancer. Single 1-mg IV and 3-mg oral doses of midazolam were given 2 days apart, in a partially random order, on study days 1, 3, 9, and 11. Lapatinib 1500-mg was administered orally once daily on study days 4 through 11. Midazolam plasma concentrations were measured up to 24-h post dosing, and lapatinib plasma concentrations measured prior to each midazolam dose.
Results
Lapatinib increased the geometric mean (95% CIs) midazolam AUC(o−∞) by 45% (31–60%) after the oral dose and by 14% (0–29%) after the IV dose, and prolonged the midazolam elimination half-life by 48% (22–81%) after the oral dose and by 20% (2–40%) after the IV dose. Lapatinib decreased midazolam total clearance by 13% (1–23%), while total bioavailability was increased 23% (4–46%) without changes in apparent volume of distribution or hepatic bioavailability.
Conclusion
These data show that lapatinib caused weak inhibition of gastrointestinal CYP3A4 in vivo. This suggests that oral CYP3A4 drug substrates with a narrow therapeutic index may need dose reduction if lapatinib is to be co-prescribed.